Fenebrutinib met primary goals in two late-stage trials for the treatment of two different forms of multiple sclerosis.

Roche said on Monday that a late-stage trial testing its multiple sclerosis drug candidate fenebrutinib against the relapsing form of the disease achieved its primary goal.

Researcher Melissa Schilling said that she was "surprised to find such a strong geographic pattern" in the U.S. distribution ...

Veralux, the state’s first dedicated whole-body MRI center, is set to open this month in the Pinnacle Hills area of Rogers.